Sheng-Chieh Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8730004/publications.pdf

Version: 2024-02-01

147801 197818 61 2,556 31 49 citations g-index h-index papers 62 62 62 2295 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma. Annals of Nuclear Medicine, 2022, 36, 256-266.	2.2	7
2	Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211101.	3.2	1
3	Multiparametric positron emission tomography/magnetic resonance imaging in nasopharyngeal carcinoma: Correlations between magnetic resonanceimaging functional parameters and 18F-fluorodeoxyglucose positron emission tomography imaging biomarkers and their predictive value for treatment failure. Tzu Chi Medical Journal. 2021. 33. 61.	1.1	3
4	Combing MRI Perfusion and 18F-FDG PET/CT Metabolic Biomarkers Helps Predict Survival in Advanced Nasopharyngeal Carcinoma: A Prospective Multimodal Imaging Study. Cancers, 2021, 13, 1550.	3.7	12
5	Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis. Diagnostics, 2021, 11, 1065.	2.6	4
6	Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. BMC Cancer, 2021, 21, 908.	2.6	6
7	Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. Diagnostics, 2021, 11, 36.	2.6	28
8	Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 94-104.	6.4	17
9	Radiation safety assessment of caregivers of thyroid cancer patients treated with 1311 in Taiwan. Radiation Physics and Chemistry, 2020, 172, 108781.	2.8	1
10	Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers, 2020, 12, 607.	3.7	9
11	Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncology, 2020, 104, 104628.	1.5	10
12	Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Annals of Nuclear Medicine, 2020, 34, 527-537.	2,2	18
13	Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS ONE, 2020, 15, e0244502.	2.5	15
14	Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Annals of Nuclear Medicine, 2019, 33, 657-670.	2.2	36
15	Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. BMC Cancer, 2019, 19, 1167.	2.6	20
16	Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (United States), 2019, 98, e16608.	1.0	10
17	Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 650-660.	6.4	26
18	Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1297-1308.	6.4	81

#	Article	IF	CITATIONS
19	Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy. Medicine (United States), 2017, 96, e7942.	1.0	4
20	Tumor heterogeneity measured on Fâ€18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epsteinâ€Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma. Laryngoscope, 2017, 127, E22-E28.	2.0	34
21	Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget, 2017, 8, 62606-62621.	1.8	30
22	Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. Oncotarget, 2017, 8, 115513-115525.	1.8	2
23	Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. European Radiology, 2016, 26, 4162-4172.	4.5	55
24	Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus. Journal of Orthopaedic Surgery and Research, 2016, 11, 52.	2.3	18
25	Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma. Medicine (United States), 2016, 95, e2567.	1.0	7
26	Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget, 2016, 7, 53217-53229.	1.8	9
27	Clinical Utility of Multimodality Imaging with Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and 18F-FDG PET/CT for the Prediction of Neck Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiation. PLoS ONE, 2014, 9, e115933.	2.5	53
28	Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World Journal of Surgical Oncology, 2014, 12, 170.	1.9	36
29	Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Annals of Nuclear Medicine, 2013, 27, 710-719.	2.2	18
30	Pretreatment 18F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 169-174.	1.5	35
31	Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 620-625.	1.5	42
32	The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 71-78.	1.5	41
33	Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma: Does Delayed Surgery Impact Outcome?. Annals of Surgical Oncology, 2013, 20, 4245-4251.	1.5	58
34	Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy. PLoS ONE, 2013, 8, e72230.	2.5	49
35	Detection of Synchronous Cancers by Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography during Primary Staging Workup for Esophageal Squamous Cell Carcinoma in Taiwan. PLoS ONE, 2013, 8, e82812.	2.5	17
36	Utility of sup > 18 / sup > F-Fluoride PET/CT and sup > 18 / sup > F-FDG PET/CT in the Detection of Bony Metastases in Heightened-Risk Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2012, 53, 1730-1735.	5.0	15

#	Article	IF	Citations
37	Prognostic Significance of ¹⁸ F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma. Journal of Nuclear Medicine, 2012, 53, 21-28.	5.0	96
38	Plasma epsteinâ€barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head and Neck, 2012, 34, 1064-1070.	2.0	57
39	Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma. Nuclear Medicine Communications, 2011, 32, 989-996.	1.1	64
40	Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncology, 2011, 47, 288-295.	1.5	57
41	PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 996-1008.	6.4	39
42	18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1607-1619.	6.4	51
43	18F-FDG PET for retropharyngeal lymph node metastasis in oropharyngeal and hypopharyngeal cancers: impact on diagnosis and prediction analysis. Nuclear Medicine Communications, 2010, 31, 260-265.	1.1	18
44	Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. European Radiology, 2010, 20, 2229-2240.	4.5	79
45	Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncology, 2009, 45, 52-58.	1.5	52
46	Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 12-22.	6.4	170
47	Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. European Radiology, 2009, 19, 2965-2976.	4.5	38
48	Pretreatment T3-4 Stage is an Adverse Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response Following Preoperative Chemoradiotherapy. Annals of Surgery, 2009, 249, 392-396.	4.2	37
49	Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of 18F-FDG PET and extended-field multi-detector row CT. Neuroradiology, 2008, 50, 969-979.	2.2	86
50	Red blood cell scintigraphy in children with acute massive gastrointestinal bleeding. Pediatrics International, 2008, 50, 199-203.	0.5	15
51	18F-FDG PET Can Replace Conventional Work-up in Primary M Staging of Nonkeratinizing Nasopharyngeal Carcinoma. Journal of Nuclear Medicine, 2007, 48, 1614-1619.	5.0	93
52	Intractable bleeding from solitary mandibular metastasis of hepatocellular carcinoma. World Journal of Gastroenterology, 2007, 13, 4526.	3.3	20
53	18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1307-1314.	0.8	43
54	Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1032-1040.	6.4	60

#	Article	IF	CITATIONS
55	Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative Neck. Journal of Clinical Oncology, 2006, 24, 4371-4376.	1.6	238
56	[18F]Fluorodeoxyglucose Positron Emission Tomography Is More Sensitive Than Skeletal Scintigraphy for Detecting Bone Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging. Journal of Clinical Oncology, 2006, 24, 599-604.	1.6	95
57	Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. Journal of Nuclear Medicine, 2006, 47, 1447-54.	5.0	21
58	False-Positive Findings on F-18 Fluoro-2-deoxy-D-glucose Positron Emission Tomography in a Patient With Nasopharyngeal Carcinoma and Extensive Sinusitis. Clinical Nuclear Medicine, 2005, 30, 62-63.	1.3	3
59	Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. International Journal of Radiation Oncology Biology Physics, 2005, 62, 501-507.	0.8	96
60	Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 541-548.	6.4	52
61	Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1073-80.	6.4	146